Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.
The agreement also provides Takeda with the option to take a license for a third target for an additional upfront fee.
|Searching for more deal information? Current Partnering offers the following options:
ImmunoGen will receive $20 million upfront and – for each target – is eligible to receive milestone payments potentially totaling up to $210 million plus royalties on the commercial net sales of any resulting ADC products.
Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this agreement.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies